331 results on '"McFadyen, James"'
Search Results
2. Mortality data from omission of early thromboprophylaxis in critically ill patients highlights the importance of an individualised diagnosis-related approach
3. Venous anomalies and thromboembolism
4. Intraindividual bleeding outcomes in patients with hemophilia A on emicizumab prophylaxis in Australia
5. Plasma from patients with vaccine-induced immune thrombotic thrombocytopenia displays increased fibrinolytic potential and enhances tissue-type plasminogen activator but not urokinase-mediated plasminogen activation
6. Between a rock and a hard place: resumption of oral anticoagulant therapy after intracranial hemorrhage
7. C-reactive protein orchestrates acute allograft rejection in vascularized composite allotransplantation via selective activation of monocyte subsets
8. A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines
9. Improving the rate of inferior vena cava filter retrieval through multidisciplinary engagement
10. Trends and risk factors for omission of early thromboprophylaxis in Australian and New Zealand ICUs between 2009 and 2020
11. Venous anomalies – an under-recognized but important cause of venous thromboembolism
12. Association between frailty, delirium, and mortality in older critically ill patients: a binational registry study
13. An Aspirin a Day…
14. Differential effects of physiological agonists on the proteome of platelet‐derived extracellular vesicles
15. Editorial: Molecular drivers of immunothrombosis
16. C-Reactive Protein and Its Structural Isoforms: An Evolutionary Conserved Marker and Central Player in Inflammatory Diseases and Beyond
17. Platelets in the Pathogenesis of Vascular Disease and Their Role as a Therapeutic Target
18. Venous Thromboembolism and Estrogen-Containing Gender-Affirming Hormone Therapy.
19. Mutational landscape, inhibitor development, and health‐care burden in non‐severe haemophilia A: A single‐centre Australian experience.
20. Caught at the Scene of the Crime: Platelets and Neutrophils Are Conspirators in Thrombosis
21. Plasma from patients with vaccine-induced immune thrombotic thrombocytopenia displays increased fibrinolytic potential and enhances tissue-type plasminogen activator but not urokinase-mediated plasminogen activation
22. A Randomized Trial of Nafamostat for Covid-19
23. Off-target drug effects on platelet function: Protecting an Achilles heel of drug development
24. Caught at the Scene of the Crime: Platelets and Neutrophils Are Conspirators in Thrombosis
25. Venous anomalies: an underrecognized but important cause of venous thromboembolism
26. Congenital fibrinogen disorders—Strengthening genotype–phenotype correlations through novel genetic diagnostic tools
27. Activated Coagulation FXII (Factor XII): A Unique Target for In Vivo Molecular Imaging
28. Combined Antiplatelet/Anticoagulant Drug for Cardiac Ischemia/Reperfusion Injury
29. Decoding the role of platelets in tumour metastasis: enigmatic accomplices and intricate targets for anticancer treatments.
30. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications
31. COVID-19 thromboembolism is reduced in ambulatory, but not hospitalized patients, following COVID-19 vaccination Short title: COVID-19 thromboembolism
32. Anticoagulation Strategies in Non–Critically Ill Patients with Covid-19
33. Treatment of haematuria with factor concentrate in people with haemophilia is associated with low rates of complications
34. A novel phosphocholine‐mimetic inhibits a pro‐inflammatory conformational change in C‐reactive protein
35. Biosimilars of anti‐vascular endothelial growth factors for ophthalmic disease – Clinical trial status 2022
36. Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19
37. A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA (BNT162b2/mRNA-1273) and adenovirus vectored vaccines (ChAdOx1-S) after the first, second and third doses
38. C-reactive protein, immunothrombosis and venous thromboembolism
39. Of Mice and Man: The Unwinding of CLEC-2 as an Antithrombotic Target?
40. Improving compliance with venous thromboembolism prophylaxis guidelines in obese inpatients
41. 2275 IVIg-exposure and thromboembolic event risk: cohort study using the UK Biobank
42. Neutrophil macroaggregates promote widespread pulmonary thrombosis after gut ischemia
43. Novel Antithrombotic Drugs on the Horizon: The Ultimate Promise to Prevent Clotting While Avoiding Bleeding
44. IVIg-exposure and thromboembolic event risk: findings from the UK Biobank
45. P2Y12 Antagonists in Cardiovascular Disease—Finding the Best Balance Between Preventing Ischemic Events and Causing Bleeding
46. Understanding vaccine‐induced thrombotic thrombocytopenia (VITT)
47. Clinical care of pregnant and postpartum women with COVID‐19: Living recommendations from the National COVID‐19 Clinical Evidence Taskforce
48. Additional file 1 of Association between frailty, delirium, and mortality in older critically ill patients: a binational registry study
49. Additional file 2 of Association between frailty, delirium, and mortality in older critically ill patients: a binational registry study
50. Factor VIII inhibitor eradication with bortezomib in acquired haemophilia A
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.